Top

American Journal of Cardiovascular Drugs

Published in:

Open Access 01-04-2017 | Review Article

Clinical Pharmacology and Cardiovascular Safety of Naproxen

Authors: Dominick J. Angiolillo, Steven M. Weisman

Published in: American Journal of Cardiovascular Drugs | Issue 2/2017

Abstract

The voluntary withdrawal of Vioxx (rofecoxib) from the market in 2004, as well as the 2005 and 2014 US FDA Advisory Committee meetings about non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk, have raised questions surrounding the use of NSAIDs in at-risk populations. This paper discusses the cardiovascular safety profile of naproxen in the context of the NSAID class. The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity, and the low COX-2 selectivity of naproxen results in a lower cardiovascular risk than that of other NSAIDs. The over-the-counter (OTC) use of naproxen is expected to pose minimal cardiovascular risk; however, the benefit–risk ratio and appropriate use should be considered at an individual patient level, particularly to assess underlying conditions that may increase the risk of events. Likewise, regulatory authorities should revisit label information periodically to ensure labeling reflects the current understanding of benefits and risks.

Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;1:CD004257.

Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database: arthritis, rheumatism, and aging medical information system. Am J Ther. 2000;7(2):115–21.CrossRefPubMed

Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594–606.CrossRefPubMed

Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005;32(11):2218–24.PubMed

Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586Findings). Rockville, MD: Substance Abuse and Mental Health Services Administration; 2010.

US Food and Drug Administration. Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee briefing document. Silver Spring, MD: US FDA; 2005. Available at: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090b1-01.htm

US Food and Drug Administration. Joint meeting of the arthritis advisory committee and the drug safety and risk management advisory committee briefing document. Silver Spring, MD: US FDA; 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdf

FitzGerald G. Presentation to the Joint Meeting of the Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. Mechanistic basis for a cardiovascular hazard from NSAIDs. 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM386452.pdf

Nissen S. Presentation to the Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The Precision Trial. 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM386446.pdf

10.

European Medicines Agency. Assessment report for Non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk. London: EMA; 2012.

11.

FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–42.CrossRefPubMed

12.

Patrono C, Patrignani P, García Rodríguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest. 2001;108:7–13.CrossRefPubMedPubMedCentral

13.

Bruno A, Tacconelli S, Patrignani P. Variability in the response to non-steroidal anti-inflammatory drugs: mechanisms and perspectives. Basic Clin Pharmacol Toxicol. 2014;114:56–63.CrossRefPubMed

14.

da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, Trelle S. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2016;387:2093–105.CrossRefPubMed

15.

Capone ML, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli MG, Patrignani P. Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2007;82:85–94.CrossRefPubMed

16.

Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Ann Rev Biochem. 2000;69:145–82.CrossRefPubMed

17.

Kean WF, Rainsford KD, Kean IR. Management of chronic musculoskeletal pain in the elderly: opinions on oral medication use. Inflammopharmacology. 2008;16:53–75.CrossRefPubMed

18.

Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11(2):81s–110s.CrossRefPubMed

19.

Goodman and Gilman (eds.). The pharmacological basis of therapeutics anti-inflammatory, antipyretic, and analgesic agents; Pharmacotherapy of Gout. 12th ed. New York: Pergamon Press; 2011.

20.

DeArmond B, Francisco CA, Lin JS, et al. Safety profile of over-the-counter naproxen sodium. Clin Ther. 1995;17:587–601.CrossRefPubMed

21.

Brune K, Renner B, Hinz B. Using pharmacokinetic principles to optimize pain therapy. Nat Rev Rheumatol. 2010;6(10):589–98.CrossRefPubMed

22.

Brune K, Furst DE. Combining enzyme specificity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability? Rheumatology (Oxford). 2007;46(6):911–9.CrossRefPubMed

23.

Brune K. Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability. Curr Med Res Opin. 2007;23(12):2985–95.CrossRefPubMed

24.

Rolf C, Engström B, Beauchard C, Jacobs LD, Li Liboux A. Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (Oxford). 1999;38(6):564–7.CrossRefPubMed

25.

Li X, Cooper MA. Measurement of drug lipophilicity and pKa using acoustics. Anal Chem. 2012;84(6):2609–13.CrossRefPubMed

26.

Hochberg MC, Altman RD, April KT, et al. American College of Rheumatology American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465–74.CrossRefPubMed

27.

Maxwell SR, Payne RA, Murray GD, Webb DJ. Selectivity of NSAIDs for COX-2 and cardiovascular outcome. Br J Clin Pharmacol. 2006;62(2):243–5.CrossRefPubMedPubMedCentral

28.

Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.CrossRefPubMedPubMedCentral

29.

Garcia-Rodriguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol. 2008;52:1628–36.CrossRefPubMed

30.

Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol. 2010;3(6):769–76.CrossRefPubMed

31.

Patrignani P, Tacconelli S, Bruno A, Sostres C, Lanas A. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin Pharmacol. 2011;4:605–21.CrossRefPubMed

32.

Reilly IA, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180–6.PubMed

33.

Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation. 2004;109(12):1468–71.CrossRefPubMed

34.

Kean WF, Lock CJ, Rischke J, Butt R, Buchanan WW, Howard-Lock H. Effect of R and S enantiomers of naproxen on aggregation and thromboxane production in human platelets. J Pharm Sci. 1989;78:324–7.CrossRefPubMed

35.

Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15.CrossRefPubMedPubMedCentral

36.

Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147–66.CrossRefPubMed

37.

Cheng JW. Use of non-aspirin nonsteroidal anti-inflammatory drugs and the risk of cardiovascular events. Ann Pharmacother. 2006;40:1785–96.CrossRefPubMed

38.

Kirkby NS, Lundberg MH, Harrington LS, et al. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A. 2012;109(43):17597–602. doi:10.1073/pnas.1209192109 CrossRefPubMedPubMedCentral

39.

Weir MR. Renal effects of nonselective NSAIDs and coxibs. Cleve Clin J Med. 2002;69(Suppl 1):S153–8.

40.

Moore N, Salvo F, Duong M, Blin P, Pariente A. Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC. Expert Opin Drug Saf. 2014;13(2):167–79.CrossRefPubMed

41.

Sowers JR, White WB, Pitt B, et al. Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. Am J Hypertens. 2003;16(S1):OR-25.

42.

Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001;110(Suppl 3A):S28–32.CrossRef

43.

MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573–4.CrossRefPubMed

44.

Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther. 2006;80(3):264–74.CrossRefPubMed

45.

Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45:1295–301.CrossRefPubMed

46.

Anzellotti P, Capone ML, Jeyam A, et al. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences. Arthritis Rheum. 2011;63:850–9.CrossRefPubMed

47.

Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287–94.CrossRefPubMed

48.

Cronberg S, Wallmark E, Söderberg I. Effect on platelet aggregation of oral administration of 10 non-steroidal analgesics to humans. Scand J Haematol. 1984;33:155–9.CrossRefPubMed

49.

Patrignani P, Tacconelli S, Piazuelo E, et al. Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. J Thromb Haemost. 2014;12(8):1320–30.CrossRefPubMed

50.

Santilli F, Rocca B, De Cristofaro R, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin “resistance”. J Am Coll Cardiol. 2009;53(8):667–77.CrossRefPubMed

51.

Yokoyama H, Yaguchi T, Suzuki Y, et al. Theoretical investigation of aspirin dosage regimen to exhibit optimal antiplatelet effects and decrease risk of upper gastrointestinal lesions. Biol Pharm Bull. 2012;35(12):2112–8.CrossRefPubMed

52.

US Food and Drug Administration. Information for healthcare professionals: comcomitant use of ibuprofen and aspirin. September 2006. Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM161282.pdf. Accessed Feb 2016.

53.

Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296:1619–32.CrossRefPubMed

54.

Bresalier RS, Sandler RS, Quan H. APPROVe Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102.CrossRefPubMed

55.

Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081–91.CrossRefPubMed

56.

Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481–92.CrossRefPubMed

57.

Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez LA, Spanish Case-Control Study to Assess NSAID-Associated ACS Risk Investigators. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol. 2010;105:1102–6.CrossRefPubMed

58.

Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J. 2006;27:1657–63.CrossRefPubMed

59.

Patrono C, Baigent C. Nonsteroidal anti-inflammatory drugs and the heart. Circulation. 2014;129:907–16.CrossRefPubMed

60.

Lee T, Lu N, Felson DT, et al. Use of non-steroidal anti-inflammatory drugs correlates with the risk of venous thromboembolism in knee osteoarthritis patients: a UK population-based case-control study. Rheumatology. 2016;55(6):1099–105.CrossRefPubMed

61.

Farkouh ME, Kirshner H, Harrington RA, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675–84.CrossRefPubMed

62.

ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1(7):e33.CrossRefPubMedCentral

63.

ESC Press Release. 2015. http://www.escardio.org/The-ESC/Press-Office/Press-releases/Last-5-years/scot-study-quells-concerns-about-nsaid-safety. Accessed Feb 2016.

64.

Baron JA, Sandler RS, Bresalier RS, et al. Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. Lancet. 2008;372:1756–64.CrossRefPubMed

65.

Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis. 2007;66:764–70.CrossRefPubMedPubMedCentral

66.

McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296:1633–44.CrossRefPubMed

67.

McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8:e1001098.CrossRefPubMedPubMedCentral

68.

Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.CrossRefPubMed

69.

US National Institutes of Health. Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT00346216. Accessed 6 Apr 2015.

70.

Pfizer Inc. Assessment of Cardiovascular Safety in NSAIDs Advisory Committee Briefing Document. 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM386446.pdf.

71.

Food and Drug Administration. Briefing Information for the February 10–11, 2014 Joint Meeting of the Arthritis Advisory Committee (AAC) and Drug Safety and Risk Management Advisory Committee (DSaRM). US Food and Drug Administration. 2014. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdf. Accessed 1 Feb 2016.

72.

Gaffney M. Statistical issues in the design, conduct and analysis of two large safety studies. Clin Trials. 2016;13(5):513–8.CrossRefPubMed

73.

Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007;115:1634–42.CrossRefPubMed

74.

Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation task force on clinical expert consensus documents. J Am Coll Cardiol. 2008;52:1502–7.CrossRefPubMed

75.

Chan FK, Abraham NS, Scheiman JM, Laine L. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First international working party on gastrointestinal and cardiovascular effects of nonsteroidal anti-inflammatory drugs and anti-platelet agents. Am J Gastroenterol. 2008;103:2908–18.CrossRefPubMed

76.

Rostam A, Moayyedi P, Hunt R; Canadian Association of Gastroenterology Consensus Group. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther. 2009;29:481–496.

77.

Bowman TS, Gaziano JM, Kase CS, Sesso HD, Kurth T. Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men. Neurology. 2006;67(5):820–3.CrossRefPubMed

78.

Yu Y, Stubbe J, Ibrahim S, et al. Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis: targeted exchange of cyclooxygenase isoforms in mice. Circ Res. 2010;106(2):337–45.CrossRefPubMed

79.

Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science. 1992;257:1276–9.CrossRefPubMed

80.

Timmers L, Sluijter JP, Verlaan CW, et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation. 2007;115:326–32.CrossRefPubMed

81.

Francois H, Athirakul K, Howell D, et al. Prostacyclin protects against elevated blood pressure and cardiac fibrosis. Cell Metab. 2005;2(3):201–7.CrossRefPubMed

82.

Polonia J, Boaventura I, Gama G, et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens. 1995;13:925–31.CrossRefPubMed

83.

Klassen D, Goodfriend TL, Schuna AA, Young DY, Peterson CA. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol. 1993;33(10):971–8.CrossRefPubMed

84.

Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477–84.CrossRefPubMed

85.

Morrison A, Ramey DR, van Adelsberg J, et al. Systematic review of trials of the effect of continued use of oral non-selective NSAIDs on blood pressure and hypertension. Curr Med Res Opin. 2007;23(10):2395–404.CrossRefPubMed

86.

Palmer R, Weiss R, Zusman RM, Haig A, Flavin S, McDonald B. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens. 2003;16(2):135–9.CrossRefPubMed

87.

Gurwitz JH, Everitt DE, Monane M, et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci. 1996;51(2):M74–9.CrossRefPubMed

88.

Houston MC, Weir M, Gray J, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med. 1995;155(10):1049–54.

89.

Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet Disord. 2007;8:73.CrossRefPubMedPubMedCentral

90.

Furey SA, Vargas R, McMahon FG. Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy. 1993;13(2):143–8.PubMed

91.

Bavry AA, Khaliq A, Gong Y, Handberg EM, Cooper-Dehoff RM, Pepine CJ. Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med. 2011;124(7):614–20.CrossRefPubMedPubMedCentral

92.

Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165:490–6.CrossRefPubMed

93.

Tegeder I, Geisslinger G. Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol. 2006;373(1):1–17.CrossRefPubMed

94.

Knights KM, Winner LK, Elliot DJ, Bowalgaha K, Miners JO. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol. 2009;68(3):402–12.CrossRefPubMedPubMedCentral

95.

Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009;169(2):141–9.CrossRefPubMed

96.

Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM. Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. Br J Clin Pharmacol. 2010;69:689–700.CrossRefPubMedPubMedCentral

97.

Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.

98.

Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, Sørensen R, Rasmussen JN, Andersen SS, Abildstrom SZ, Traerup J, Poulsen HE, Rasmussen S, Køber L, Torp-Pedersen C. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–7.CrossRefPubMed

Title: Clinical Pharmacology and Cardiovascular Safety of Naproxen
Authors: Dominick J. Angiolillo
Steven M. Weisman
Publication date: 01-04-2017
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 2/2017
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.1007/s40256-016-0200-5

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Pharmacology and Cardiovascular Safety of Naproxen

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective

The Rationale for and Clinical Pharmacology of Prasugrel 5 mg

Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study

Therapeutic Targeting of Cellular Stress to Prevent Cardiovascular Disease: A Review of the Evidence

Pitavastatin: A Review in Hypercholesterolemia

Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page